MET and non-small cell lung carcinoma: This compendium also enriched combination biomarkers (N = 63), extending the definition of a biomarker beyond a single genotype, to emphasise their emerging roles in informing therapy (e.g., targeting both c-MET amplification in EGFR-mutated NSCLC has been studied as a strategy to overcome secondary resistance to gefitinib37).